DOAJ Open Access 2021

An exceptional response to 177LuPSMA undermined by neuroendocrine transformation

Pretoria Bilinski Myles Webb

Abstrak

Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). 177Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy for mCRPC patients who have exhausted other systemic therapy options; however, cells with neuroendocrine differentiation do not express PSMA and are not affected by this treatment. This case highlights an exceptional response of skeletal metastases to 177LuPSMA that is undermined by neuroendocrine transformation in the liver.

Topik & Kata Kunci

Diseases of the genitourinary system. Urology

Penulis (2)

Pretoria Bilinski

Myles Webb

Format Sitasi

APA MLA BibTeX

Bilinski, P., Webb, M. (2021). An exceptional response to 177LuPSMA undermined by neuroendocrine transformation. https://doi.org/10.1016/j.eucr.2020.101467

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.1016/j.eucr.2020.101467

Informasi Jurnal

Tahun Terbit: 2021
Sumber Database: DOAJ
DOI: 10.1016/j.eucr.2020.101467
Akses: Open Access ✓